ClinicalTrials.gg
Not yet recruitingNCT06989047Updated May 25, 2025

Ultrasound-Guided PENG Block vs Femoral Nerve Block for Analgesia Before Spinal Anesthesia in Hip Fracture Surgery

An interventional study of Pericapsular Nerve Group (PENG) Block and Femoral Nerve Block (FNB) in Proximal Femur Fracture, Hip Fracture and Pain Management, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare two types of ultrasound-guided nerve blocks-Pericapsular Nerve Group (PENG) block and Femoral Nerve Block (FNB)-to evaluate their effectiveness in reducing pain before spinal anesthesia in patients who will undergo surgery for proximal femur fractures. Proximal femur fractures will continue to be common, especially in older adults, and often will cause severe pain that will make it difficult to position patients for spinal anesthesia. Both nerve blocks will aim to reduce pain, improve comfort during spinal anesthesia, and decrease the need for postoperative pain medication.

A total of 60 adult patients who will undergo proximal femur fracture fixation under spinal anesthesia will be enrolled and randomly assigned to receive either a Pericapsular Nerve Group (PENG) block or a femoral nerve block before the procedure. The study will monitor patients' pain scores using the Visual Analog Scale (VAS) at multiple time points, including during positioning and throughout the first 24 hours after surgery. It also will evaluate how long it will take before the patients require rescue pain medication, and how much total pain medication will be needed.

02

Conditions studied

  • Proximal Femur Fracture
  • Hip Fracture
  • Pain Management
  • Spinal Anesthesia

Keywords

  • Pericapsular Nerve Group Block (PENG)
  • Femoral Nerve Block (FNB)
  • Ultrasound-Guided Nerve Block
  • Spinal Anesthesia
  • Hip Surgery
  • Regional Anesthesia
03

In context

Proximal Femoral Fractures

36 studies on the registry are indexed under Proximal Femoral Fractures; 6 are open to participants now.

This study's planned enrollment of 60 is below the median of 68 across 22 interventional studies indexed under Proximal Femoral Fractures.

Browse Proximal Femoral Fractures studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Scheduled for proximal femur fracture fixation under spinal anesthesia
  • Classified as (ASA) physical status I, II, or III
  • Ability to understand and use the Visual Analog Scale (VAS)
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Coagulopathy
  • Local infection at the injection site
  • Known allergy to local anesthetics or magnesium sulfate
  • Severe cardiopulmonary disease [ (ASA) ≥ IV]
  • Preexisting diabetic or other neuropathies
  • Chronic opioid use
  • to spinal anesthesia
  • Cognitive impairment or inability to comprehend Visual Analog Scale (VAS)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PENG Block Group

    Assigned Interventions: Procedure/Surgery: Pericapsular Nerve Group (PENG) Block An ultrasound-guided nerve block targeting articular branches of the femoral, obturator, and accessory obturator nerves. Performed under aseptic technique using a curved low-frequency ultrasound probe to visualize the iliopsoas plane and pubic ramus. Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used to provide analgesia in nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct used to enhance analgesic efficacy of the block.

    Procedure: Pericapsular Nerve Group (PENG) Block

  • Active comparator
    Femoral Nerve Block Group

    Assigned Interventions: Procedure/Surgery: Femoral Nerve Block (FNB) An ultrasound-guided nerve block targeting the femoral nerve, performed with an in-plane ultrasound approach under sterile conditions, identifying the nerve lateral to the femoral artery. Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used for nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct analgesic agent.

    Procedure: Femoral Nerve Block (FNB)

Interventions

  • ProcedurePericapsular Nerve Group (PENG) Block

    Assigned Interventions: Procedure/Surgery: Pericapsular Nerve Group (PENG) Block An ultrasound-guided nerve block targeting articular branches of the femoral, obturator, and accessory obturator nerves. Performed under aseptic technique using a curved low-frequency ultrasound probe to visualize the iliopsoas plane and pubic ramus. Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used to provide analgesia in nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct used to enhance analgesic efficacy of the block.

  • ProcedureFemoral Nerve Block (FNB)

    An ultrasound-guided nerve block targeting the femoral nerve to provide analgesia before spinal anesthesia in proximal femur fracture surgery. Administered using 30 ml of 0.25% bupivacaine and 5 ml of 10% magnesium sulfate (500 mg). The block is performed with an in-plane ultrasound approach, identifying the femoral nerve lateral to the femoral artery under sterile conditions.

06

What researchers measure

Primary outcomes

  1. Pain Score During Positioning for Spinal Anesthesia Using Visual Analog Scale (VAS)

    The Visual Analog Scale (VAS) will be used to assess pain intensity during positioning for spinal anesthesia. The VAS is a 10 cm line where 0 indicates no pain and 10 indicates the worst imaginable pain. The score will be recorded immediately before spinal anesthesia after performing either the PENG block or femoral nerve block.

    Time frame: Immediately before spinal anesthesia (within 15 minutes post-block)

  2. Time to First Rescue Analgesia

    The time (in hours) from the end of the nerve block to the first request for additional analgesia (nalbuphine 0.2 mg/kg IV) will be recorded for each patient.

    Time frame: Within 24 hours postoperatively

Secondary outcomes

  1. Total Nalbuphine Consumption

    The cumulative dose (in mg) of intravenous nalbuphine administered for pain control will be calculated for each participant over the first 24 hours following surgery.

    Time frame: 24 hours postoperatively

  2. Mean Arterial Pressure (MAP) Changes

    Mean arterial pressure will be recorded at baseline (pre-block), then at 2, 5, 10, 15 minutes post-block, and subsequently at 2, 6, 12, 18, and 24 hours after surgery to evaluate hemodynamic stability following either pericapsular nerve block (PENG) block or femoral nerve block.

    Time frame: From baseline up to 24 hours postoperatively

  3. Patient Satisfaction Score

    Patient satisfaction with pain control will be evaluated using a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied) at the end of the 24-hour postoperative period.

    Time frame: At 24 hours postoperatively

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for May 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 25, 2025
StartEst.
May 30, 2025
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2026
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989047
Responsible party
Mohamed Khaled Radwan Ammar (Resident of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Ain Shams University) — Principal investigator
First posted
May 25, 2025
Start date
May 30, 2025 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
May 25, 2025

Study contacts

Mohamed K Ammar, M.B.B.Ch
Contact
Mohamed_Khaled@med.asu.edu.eg
01153702277 ext. +2

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion